Literature DB >> 10933456

Intravenous gammaglobulin treatment in chronic progressive multiple sclerosis.

G Salemi, L Manfrè, S Monaco, T Angileri, P Aridon, S Pappalardo, P Ragonese, S Conte, G Savettieri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 10933456     DOI： 10.1007/bf00713862

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN： 0392-0461


× No keyword cloud information.
  6 in total

1.  A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.

Authors:  F G van der Meché; P I Schmitz
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

2.  Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.

Authors:  A Achiron; U Gabbay; R Gilad; S Hassin-Baer; Y Barak; M Gornish; A Elizur; Y Goldhammer; I Sarova-Pinhas
Journal:  Neurology       Date:  1998-02       Impact factor: 9.910

3.  Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.

Authors:  F Fazekas; F Deisenhammer; S Strasser-Fuchs; G Nahler; B Mamoli
Journal:  Lancet       Date:  1997-03-01       Impact factor: 79.321

4.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

5.  Intravenous gamma globulin in progressive MS.

Authors:  S D Cook; R Troiano; C Rohowsky-Kochan; A Jotkowitz; L Bielory; P D Mehta; J Oleske; S Bansil; P C Dowling
Journal:  Acta Neurol Scand       Date:  1992-08       Impact factor: 3.209

6.  The use of intravenous immune globulin in collagen vascular disorders: a potentially new modality of therapy.

Authors:  E W Gelfand
Journal:  J Allergy Clin Immunol       Date:  1989-10       Impact factor: 10.793
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.